Compare CLMT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | ANIP |
|---|---|---|
| Founded | 1916 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2024 | 1999 |
| Metric | CLMT | ANIP |
|---|---|---|
| Price | $27.99 | $74.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $23.25 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.2M | 345.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 85.39 | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | ★ $4,137,100,000.00 | $206,547,000.00 |
| Revenue This Year | $4.45 | $23.05 |
| Revenue Next Year | N/A | $14.08 |
| P/E Ratio | ★ N/A | $22.52 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $7.68 | $56.71 |
| 52 Week High | $31.41 | $99.50 |
| Indicator | CLMT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 45.15 |
| Support Level | $26.41 | $71.29 |
| Resistance Level | $30.67 | $77.47 |
| Average True Range (ATR) | 1.49 | 2.40 |
| MACD | -0.33 | 0.23 |
| Stochastic Oscillator | 22.27 | 54.64 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.